Skip to content
ES
MARKETS / NYSE / MLSS
NYSE · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · SMALL CAP

Milestone Scientific Inc. MLSS

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$9.0M
▲ 4.0% YoY
$-5.7M
$-2.9M
In brief

What this company does

The Company develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. In the dental market, the Company’s products are marketed under the CompuDent® and STA Single Tooth Anesthesia System® trademarks and utilize The Wand®, a single-use disposable handpiece. In the medical market, the Company has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its CompuFlo® Epidural Computer Controlled Anesthesia System for use in specified regions of the spine.

Written from the business description in Milestone Scientific Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
USD 9.0M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 9.0 · Net income -5.7
4M8M-4M-8M201020122014201620182020202220242025
Compound annual growth
+0.6%
+10.5%
−0.6%
−0.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +10.5% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−64 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -63.5% · Net -63.8%
-50%-100%201020122014201620182020202220242025
ROE
FY2025 · ROE -132.4%
-200%-400%201020122014201620182020202220242025
Gross margin71.4%
Operating margin-63.5%
Net margin-63.8%
Return on assets-65.0%
EBITDAUSD -5.7M

Each USD of equity lost 132 cents this year.

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -2.9
0.5M1.0M-2.5M-5.0M201020122014201620182020202220242025
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Total assetsUSD 7.8M
EquityUSD 2.8M
CashUSD 1.1M
Current ratio1.81×

Equity funds 36% of total assets.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0
Income tax $B··0.00.00.00.00.00.00.0−0.00.00.0····
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0·−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.00.0−0.0−0.0−0.0
EPS, diluted $−0.07−0.06··−0.10−0.12−0.16−0.21−0.16−0.22−0.26−0.080.08−0.05−0.10·
Dividend / sh $················
Payout %················
ROE %−132.4−68.1−76.0−65.5−41.9−82.0−465.1−169.2−65.9−63.2−43.8−16.939.3−44.9−69.4−26.3
Shares out B0.080.080.080.070.070.060.050.030.030.030.020.020.020.020.020.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 79 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 16 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityOrthopedic, Prosthetic & Surgical Appliances & Supplies
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image